With cancer cases rapidly rising, there is a dire need for highly efficient therapies such as CAR-T cell therapy. Currently, the production of CAR-T cells involves a long and costly manufacturing process, notably because of its autologous nature and the use of viral vectors, which hampers accessibility of the treatment to patients. To solve these limitations, iPSC-derived allogeneic CAR-T cells engineered in a non-viral manner is a promising alternative. However, while electroporation is the state-of-the-art non-viral transfection technology for generating CAR-T cells, it also induces a lot of cell death in combination with important phenotypic changes that lead to decreased therapeutic potency. Moreover, iPSC differentiation into mature T cells is often not very efficient, requiring prolonged ex vivo expansion, and leading to exhaustion or other undesired phenotypic changes. To overcome these difficulties, we propose to produce allogeneic CAR-T cells by inserting a CAR sequence at the TRAC locus of iPSCs using photoporation, a novel minimally perturbing gene transfection technology. To enhance the differentiation efficiency, TNF signaling will be activated via targeting TNF receptor 2, which was recently discovered to improve the generation of developmentally competent T precursors from blood progenitor cells. Hence, we will exploit photoporation and TNF signaling as key technologies for generating iPSC-derived CAR-T cells.